Holen Sie sich die Stockscreener-App
3.77
0.27%
0.01
Neuphoria Therapeutics Inc Aktie (NEUP) Neueste Nachrichten
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 90.9% EPS SurpriseGeographic Revenue Trends - Vinanet
Neuphoria Therapeutics (NEUP) Pulls Back to $3.82 as Traders Eye Key Support ZoneVanna Flow - dars.gov.et
Neuphoria Therapeutics (NEUP) Pulls Back 1.27% to $3.9, Holds Above Key SupportKeltner Channel - dars.gov.et
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? - tradingview.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Neuphoria Therapeutics (NEUP) Slips to $3.88 as Bulls Defend Key SupportSector ETF Flow - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Lean Cost ManagementEarnings Decline Risk - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 90.9% EPS Surprise Amid Stock PullbackEarnings Weakness Phase - Vinanet
Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial - allsci.com
Neuphoria Therapeutics (NEUP) Holds Near $3.93 as Biotech Stock Tests Key Technical LevelsStock Analysis - vinanet.vn
Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14Chandelier Stop - dars.gov.et
Advising Nasdaq-listed Neuphoria Therapeutics Inc. On Its USD250M Merger With AIM-listed Scancell Holdings - Mondaq
Neuphoria Therapeutics Inc. (NEUP) Q2 2026 Earnings: Loss Narrows Sharply, Exceeding ExpectationsEPS Growth Report - dars.gov.et
Advising Nasdaq-listed Neuphoria Therapeutics Inc. on its USD250M merger with AIM-listed Scancell Holdings - Winston Taylor
Halper Sadeh LLC is Investigating Whether SAFT, NEUP, NRIM are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Neuphoria Therapeutics Inc (NEUP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neuphoria Therapeutics Inc (NASDAQ: NEUP) Share Price, NEUP Stock News, NEUP Share Price & Updates - Kalkine
NEUP|Neuphoria Therapeutics Inc|Price:3.970|Chg%:+0.330 - TradingKey
Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuphoria Therapeutics Inc (NEUP) Income Statement - tradingkey.com
Neuphoria Therapeutics (NEUP) Drops 7%: Key Levels in Focus After Sharp DeclineFibonacci Time Zone - po-news-eg.net
Neuphoria Therapeutics Inc. Revenue Breakdown – NASDAQ:NEUP - TradingView
NEUP|Neuphoria Therapeutics Inc|Price:3.810|Chg%:+0.170 - TradingKey
Neuphoria Therapeutics Inc (NEUP) Cash Flow - TradingKey
Neuphoria Therapeutics Market Sentiment - Benzinga España
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Monteverde & Associates investigates Neuphoria Therapeutics merger fairness for shareholders. - Pluang
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) - PR Newswire
Neuphoria Therapeutics (NEUP) Proxy filing Summary - Quartr
Neuphoria Therapeutics to Merge with Scancell Holdings - TipRanks
Neuphoria Therapeutics (Nasdaq: NEUP) to be acquired by Scancell - Stock Titan
Neuphoria Therapeutics to Merge With Scancell; Holders to Receive ADSs Plus CVRs - TradingView
Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing - Yahoo Finance UK
NEUPHORIA THERAPEUTICSSCANCELL EXPECTS TO SECURE UP TO $89 MLN IN FINANCING - Moomoo
Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell - Moomoo
Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $34.7 million. - marketscreener.com
Scancell, Neuphoria Therapeutics Agree All-share Merger - Moomoo
Scancell merges with Neuphoria after Merck axes trial; AstraZeneca breast cancer drug approved in EU - Endpoints News
Scancell agrees to buy Neuphoria, combined firm set to list on Nasdaq - marketscreener.com
Scancell And Neuphoria Therapeutics Announce Merger Agreement - TradingView
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing - The Manila Times
Scancell And Neuphoria Therapeutics Announce Merger Agreement And Financing - TradingView
Scancell to join Nasdaq through Neuphoria merger and $89 million funding package - Proactive financial news
Scancell Holdings Secures £9 Million via UK Share Placing Ahead of Nasdaq Merger with Neuphoria Therapeutics - Kalkine Media
MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership - MSN
Price to book forward of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
Enterprise value to revenue forward of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
Price to earnings forward of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
Enterprise value to EBITDA forward of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
Price to sales forward of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
Neuphoria Therapeutics (NEUP) Slips 1.26% as Stock Tests Key Support ZoneVolume Nodes - dars.gov.et
Neuphoria announces initiation of strategic review - MSN
Number of shareholders of Neuphoria Therapeutics Inc. – NASDAQ:NEUP - TradingView
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership - Stocktwits
Neuphoria Therapeutics Inc. (NEUP) Q2 2026 Earnings: Narrower-than-Expected Loss Sparks Positive Reaction - dars.gov.et
NEUP Q2 2026 Earnings: Significant EPS Beat Driven by Cost ManagementEarnings Cycle Report - dars.gov.et
NEUPNeuphoria Therapeutics Inc Latest SEC Filings - Finviz
NEUP Q2 2026 Earnings: Significant EPS Beat Driven by Lower-than-Expected Operating ExpensesOperating Margin Analysis - po-news-eg.net
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):